top of page
LogoWix.jpg
Search

Regenerative Research Roundup - March 2026

Welcome to the Regenerative Research Roundup, where we look through recently published research and bring you the best of the best in a quick-to-read digest.


This month, we explore:

  • Dose-dependent risk of accelerating knee arthroplasty with corticosteroid injection

  • Expert-driven recommendations on viscosupplementation on hip OA

  • PRP reducing tear-volume articular‑sided partial supraspinatus tendon tears

  • PRP as an adjunct to microfracture for chondral lesions

  • Head-to-head comparison of PRP+HA combination therapy versus HA mono-injection for knee OA

 

Let's dive in!


________________________________________________________________


Intra-articular corticosteroid injections are associated with a dose-dependent risk of total knee arthroplasty at 5 years


Knee Surgery, Sports Traumatology, Arthroscopy // LOE: III


Retrospective cohort analysis using the Pearl Diver dataset (2010–2020), identifying adults with unilateral knee pain without a diagnosis of knee OA who did or did not receive an intra‑articular corticosteroid injection (CSI), then tracking TKA incidence at 5 years.


Key Findings:

  • At 5 years, a higher incidence of TKA was observed in the CSI cohort compared to the non-CSI cohort

  • Dose-response relationship by CSI injection count corresponding to 5-year TKA risk was observed. With 2 injections showing 2x risk, and ≥3 injections displaying a 3.8x risk versus no injection.

  • The average time to TKA was shorted in relation to the number of CSI. At 1 CSI, the time-to TKA was 3.03 ± 2.29 years. At 3 CSI, the time-to TKA was 1.78 ± 0.80 years.


Clinical Perspective:


This study cleverly excluded knee OA patients, preventing OA severity to obscure TKA predictability. However, while reinforcing a key counseling point: repeat CSI exposure correlates with higher downstream TKA risk indicated by a dose‑dependent relationship with higher injection counts linked to fast progression to arthroplasty. Corticosteroids are a double-edged sword, providing short term symptom control at the consequence of rapidly accelerating TKA in non-knee OA patients, through structural deterioration and greater cartilage loss.


For sports-MSK clinics' regenerative toolkit, CSI use should be limited, taking into consideration other symptom-modifying pathways and biologics for structural regeneration.


________________________________________________________________


EUROVISCO Recommendations for the Use of Viscosupplementation with Hyaluronic Acid in the Management of Hip Osteoarthritis


Cartilage // LOE: V 


The EUROVISCO group, consisting of 12 European experts across rheumatology, orthopedics, and rehabilitation, used a Delphi voting across statements to make 23 recommendations regarding intra‑articular HA viscosupplementation for hip OA, grounded in literature review and clinical experience. The panel reached high consensus on 16 statements.


Key Findings:

  • The panel unanimously supported and strongly in favor of HA viscosupplementation for hip OA patients not requiring surgery.

  • The panel unanimously agreed and strongly in favor that hip VS is safe and well tolerated, even in the case of repeated injections

  • The panel unanimously recommended hip VS should be performed under imaging guidance (ultrasound or fluoroscopy) to ensure accurate intra‑articular placement.

  • The panel unanimously agreed that HA VS is more effective in mild to moderate hip OA rather than severe disease progression.


Clinical Perspective:


This Delphi consensus study is highly applicable to day-to-day clinical practice, translating the complex evidence landscape into clear, expert-driven guidance. Experts were able to unanimously define appropriate patient selection, treatment boundaries, safety and provide clinicians with a practical decision-making framework for the use of hyaluronic acid viscosupplementation in hip osteoarthritis.


________________________________________________________________


Addition of Platelet‑Rich Plasma to Physiotherapy Reduces Tear Volume and Improves Functional Outcomes in Articular‑Sided Partial Supraspinatus Tendon Tears


Knee Surgery, Sports Traumatology, Arthroscopy // LOE: II


This single‑centre prospective randomized controlled trial enrolled 63 patients aged 25–65 years with isolated articular‑sided partial‑thickness supraspinatus tendon tears confirmed on magnetic resonance arthrography (MRA). Patients were randomized to physiotherapy (control arm) or physiotherapy + 2 ultrasound-guided PRP injections (treatment arm), with the primary outcomes focused on radiological changes in tear volume on MRA, while secondary outcomes included pain (VAS) and shoulder function (Constant–Murley Score), assessed before and after treatment.

 

Key Findings

  • Patients treated with PRP plus physiotherapy demonstrated a significantly greater reduction in supraspinatus tear volume on MRI/MRA compared with physiotherapy alone.

  • Both treatment and control arms experience significant improvement in VAS and CMS scores. However, in the evaluation of CMS scores, a significantly greater improvement was observed in the PRP group compared to the control group.

 

Clinical Perspective:


This study is notable because it moves beyond symptom‑based outcomes and demonstrates objective structural improvement on imaging following PRP treatment. However, interpretation of these results requires contextualization of the platelet preparation used.  While platelet concentration, leukocyte composition, and total platelet dose remain undisclosed, this may suggest that even modest PRP formulations not only enhance functional recovery but also correspond to a measurable reduction in tendon tear volume on MRI.


For clinicians managing tendinopathies and chronic injuries, these findings support PRP as a biologic adjunct that may influence tendon healing itself rather than just pain relief. This study also indirectly reinforces the role of image guidance in accurately delivering biologic therapies to the intended tissue target.

 

________________________________________________________________


Efficacy and safety of a combination of platelet-rich plasma with non-crosslinked hyaluronic acid versus a crosslinked hyaluronic acid, in single-injection for knee osteoarthritis. Randomized, controlled, multicenter, non-inferiority trial 


BMC Musculoskeletal Disorders // LOE: I 


Randomized, single-blind non-inferiority trial in 156 patients (ages 40-80) with K-L grade II–III symptomatic knee OA, comparing single-injection PRP and non-crosslinked HA combination therapy vs single-injection crosslinked HA with follow-up at 1, 3, and 6 months; an open-label PRP-HA extension was offered to patients still symptomatic at 6 months.


Key Findings:

  • The PRP-HA group demonstrated significant improvement in the WOMAC for pain on walking at 6 months.

  • The percentage of responders in favor of PRP-HA at 6 months was higher for PASS WOMAC Pain (50.6% vs. 33.3%, p = 0.04)

  • A greater analgesic effect was observed in the PRP-HA group compared to the HA group at month 1.

  • No significant differences observed at 6 months for OMERACT–OARSI responders or MCII WOMAC pain


Clinical Perspective:


While this study is framed as a comparison between the combination therapy of PRP with a non-cross-linked HA versus a cross-linked HA, the more meaningful interpretation is a comparison between a low-dose biologic combination therapy and a high-quality HA mono-injection. The PRP formulation used was not characterized in terms of platelet count, platelet concentration, or leukocyte composition. However, using the Cellular Matrix (RegenLab) preparation method, the delivered PRP dose is <1.5x baseline at best, according to prior reported data for RegenLab. Similarly, the HA used for the mono-injection was Synvisc-One, a high-molecular-weight, high-quality HA solution.  

 

In this context, the absence of superiority of a PRP-HA combination over cross-linked HA is not surprising, considering that the comparison is being made between a low-quality PRP in combination with a low-quality HA and a high-quality HA product. This study fails to effectively evaluate quality PRP + HA as a combination therapy or compare cross-linked HA to uncross-linked HA, inadvertently leading to no meaningful conclusions.

 

________________________________________________________________

 


 
 
 
bottom of page